Search

Background: Diabetes is a chronic condition associated to higher levels of systemic oxidative stress. This might pose a risk of failure for implant therapies. However, there is insufficient data regarding the long-term implant survival in patients with diabetes assessing different implant designs and complementary information related to patients’ general oral health status. The aim of this cohort study was to investigate the survival and success rates of titanium-zirconia tissue-level dental implants in patients with a history of T2DM and to assess the outcome according to glycemic control and oxidative stress levels.Methods: The present cross-sectional study evaluated the implant success among a cohort of patients diagnosed with diabetes type II and rehabilitated with titanium-zirconia tissue-level implants. Blood and salivary oxidative stress has been scored at different time points with U CARR units. Results: Thirty-seven implants in twenty-eight patients have been included in the analysis. All implants were healthy, not showing pathological bone loss neither signs or symptoms of mucositis/peri-implantitis at the last follow-up visit. Local and systemic stress appeared unrelated. The blood test scored an average value of 367±71.8 U CARR which is to be expected in a diabetic cohort, with no difference on the basis of glycemic control. The average salivary test score was 2203±364 U CARR, which is within the limits of a healthy range. This test was found to be higher in diabetic patients showing poor glycemic control. Conclusion: Tissue level implants are a reliable solution in diabetic patients with varying levels of glycemic control and systemic oxidative stress, as long as the general oral health is preserved. Assessment of salivary antioxidants could be a non-invasive beneficial procedure to routing patients to the appropriate treatment plan, discouraging elective surgical procedure unless strict hygiene measures are followed.

This study aimed to evaluate the efficacy of diode laser for the surgical treatment of neurofibromas (NF), in terms of clinical outcome and therapeutic success.The NF is a benign tumor of the peripheral nerve sheath, characterized by the proliferation of Schwann cells, perineural cells, and endoneural fibroblasts. NF may occur as a solitary lesion, or as part of a generalized neurofibromatosis syndrome; much more rarely it occurs in the form of multiple neurofibromas with no associated syndrome. Two distinct variants of neurofibromatosis have been described: types I and II.Ten cases are reported (6 women and 4 men, age range 43-70 years) with smooth, painful, or painless lesions of the oral mucosa. Lesions were completely excised using a diode laser at 980 nm wavelength, average power 2.0 W, in continuous wave mode, with 320 μm optical fibers, for 45 sec average time.Complete healing occurred within 20 days. There were no adverse effects; patients were carefully followed up and there have been no recurrences after an interval of 3 months to 3 years.The results of this diode laser treatment of NF demonstrate good effectiveness of this novel therapy, which may replace conventional surgical procedures.